1-(1-butyl-2,4-diphenyl-1H-imidazol-5-yl)-N-[4-(trifluoromethoxy)benzyl]-N-[3-(trifluoromethyl)benzyl]methanamine | 610289-47-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(1-butyl-2,4-diphenyl-1H-imidazol-5-yl)-N-[4-(trifluoromethoxy)benzyl]-N-[3-(trifluoromethyl)benzyl]methanamine
• 英文别名: N-[(3-butyl-2,5-diphenylimidazol-4-yl)methyl]-1-[4-(trifluoromethoxy)phenyl]-N-[[3-(trifluoromethyl)phenyl]methyl]methanamine
• CAS: 610289-47-9
• 化学式: C₃₆H₃₃F₆N₃O
• 分子量: 637.668
• InChiKey: QMBVOZQBEFDTKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.4
• 重原子数：
  46
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30.3
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS
  申请人：NEUROGEN CORPORATION

  公开号：EP1490044A1

  公开（公告）日：2004-12-29
• EP1490044A4
  申请人：——

  公开号：EP1490044A4

  公开（公告）日：2008-04-16
• US7186734B2
  申请人：——

  公开号：US7186734B2

  公开（公告）日：2007-03-06
• US8119665B2
  申请人：——

  公开号：US8119665B2

  公开（公告）日：2012-02-21
• [EN] COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS<br/>[FR] THERAPIE COMBINATOIRE POUR LE TRAITEMENT DE MALADIES FAISANT INTERVENIR DES COMPOSANTS INFLAMMATOIRES
  申请人：NEUROGEN CORP

  公开号：WO2003084524A1

  公开（公告）日：2003-10-16

  Compositions and methods for treating diseases that are associated with inflammation are provided. Such diseases include arthritis (particularly rheumatoid arthritis) and other autoimmune disorders, asthma, cardio-and cerebrovascular disease, burns, psoriasis, reperfusion injury, and traumatic CNS and spinal cord injury. The compositions generally comprise at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent. The methods involve co-administration of at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent to a patient. The C5a antagonist and C5a receptor-inactive therapeutic agent may be present within the same composition, or may be administered separately to the patient.